WEY Wolfeye Resource Corp

LexaGene Featured on ABC Affiliate WCVB-TV Boston

LexaGene Featured on ABC Affiliate WCVB-TV Boston

BEVERLY, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops instrumentation and assays for pathogen detection, today announced that the Company was featured on ABC-affiliated television station WCVB Boston on a segment of ‘Cutting Edge’ on December 21, 2018. Following the initial airing, the segment is scheduled to air several more times in the coming weeks on other ABC-affiliated channels. .

“We were very honored to be featured in ABC’s ‘Cutting Edge’ Program and to have the opportunity to showcase LexaGene’s vision and the impact this technology can have on the world. The segment producers look for companies working on solutions to everyday problems that are of interest to their viewers. These viewers will likely remember 2018 as a horrible year for foodborne illnesses, as the CDC investigated 28 outbreaks compared to the eight investigated in 2017. To help solve this problem, LexaGene is developing a low-cost – yet extremely sensitive – pathogen detection instrument that will provide food safety officers at food processing and packaging facilities with a more rapid assessment on the safety of their products,” states Dr. Jack Regan, LexaGene’s CEO and Founder.

To be added to the LexaGene email distribution list, please subscribe on the Company website .

About LexaGene Holdings Inc.

LexaGene is a biotechnology company developing the very first fully automated pathogen detection platform that is open-access.  The open-access feature will empower end-users to target any pathogen of interest, as they can load their own real-time PCR assays onto the instrument for customized pathogen detection.  End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, and press ‘go’. The instrument is expected to offer excellent sensitivity, specificity, and breadth of pathogen detection.  The instrument will be able to process multiple samples at a time, in an on-demand fashion, returning results in about 1 hour. The company expects to sell its technology in the food safety market, veterinary diagnostics market and more.  

About WCVB Channel 5

WCVB is Boston’s broadcast/digital media leader, providing news, weather, sports, community service and entertainment on multiple platforms including WCVB Channel 5, wcvb.com, WCVB mobile and MeTV Boston. Founded by community leaders in 1972, WCVB is committed to its mission to serve the region with quality local content. In addition to 47 hours of NewsCenter 5 coverage each week, original offerings include Chronicle, the nation’s longest running local news magazine; CityLine, a weekly urban magazine program; and On The Record, a weekly political roundtable. The station has been honored with numerous prestigious national broadcasting honors including the RTDNA Edward R. Murrow Awards for “Best Newscast” and National Association of Broadcasters Education Foundation’s “Service to the Community” award. Additional top honors include the National Headliner Awards, Gracie Awards, Gabriel Awards, the regional Emmy’s, Associated Press Awards, Walter Cronkite Award, and duPont Awards. WCVB, Boston’s ABC affiliate station, is owned by Hearst Television, a wholly owned subsidiary of Hearst, a leading media company whose global holdings include 30 television stations and two radio stations.

Media Contacts

Nicole Ridgedale

Director of Corporate Marketing, LexaGene

800.215.1824 ext 206

Investor Relations

Jay Adelaar

Vice President of Capital Markets, LexaGene

800.215.1824 ext 207

The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors -- including the availability of funds, the results of financing efforts, the success of technology development efforts, the cost to procure critical parts, performance of the instrument, market acceptance of the technology, regulatory acceptance, and licensing issues -- that could cause actual results to differ materially from the Company's expectations as disclosed in the Company's documents filed from time to time on SEDAR (see ). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

EN
03/01/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Wolfeye Resource Corp

 PRESS RELEASE

LexaGene Files for Chapter 7 Bankruptcy

LexaGene Files for Chapter 7 Bankruptcy BEVERLY, Mass., Feb. 24, 2023 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), announces that it has ceased operations, laid off its staff, and, together with its direct subsidiary LexaGene, Inc., and its indirect subsidiary Bionomics Diagnostics, Inc., filed a voluntary petition for relief under Chapter 7 of the U.S. Bankruptcy Code. The filing, which took place earlier today at the U.S. Bankruptcy Court for the District of Massachusetts, located in Boston, Massachusetts, will result in federal ...

 PRESS RELEASE

LexaGene Provides Update on BioPharma Sector

LexaGene Provides Update on BioPharma Sector BEVERLY, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- , (; ) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has commercialized the for automated, genetic testing, is pleased to provide the following update on the Company’s efforts to have the MiQLab System adopted for routine testing during the manufacturing of biologics. Dr. Jack Regan, CEO and Founder of LexaGene commented, “We continue to work with both of our biopharma customers - a more traditional biopharma company with a market cap that is >$100B and a l...

 PRESS RELEASE

LexaGene’s MiQLab System Detects Mycoplasma at Minute Levels, Rousing ...

LexaGene’s MiQLab System Detects Mycoplasma at Minute Levels, Rousing Additional Interest from BioPharma Customers BEVERLY, Mass., Jan. 18, 2023 (GLOBE NEWSWIRE) -- , (; ) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has commercialized the for automated, genetic testing, is pleased to announce exciting news regarding the ability of the MiQLab System to detect Mycoplasma at minute levels. Dr. Jack Regan, CEO and Founder of LexaGene commented, “In the process of completing the follow-on feasibility study with one of our biopharma customers, I’m thrilled...

 PRESS RELEASE

BioPharma Engages LexaGene in Second Feasibility Study

BioPharma Engages LexaGene in Second Feasibility Study Cancels Plans to Reprice Meridian’s Warrants BEVERLY, Mass. , Dec. 16, 2022 (GLOBE NEWSWIRE) -- , (; ) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has commercialized the for automated, genetic testing, is pleased to announce the large biopharma company (>$100B Market Cap) that previously purchased a MiQLab System has engaged LexaGene in a second statement of work (“SOW”) that builds off of the previously completed SOW. Dr. Jack Regan, LexaGene’s CEO and Founder commented, “In the biopharma indu...

 PRESS RELEASE

LexaGene Holdings Proposes to Amend Warrants Terms

LexaGene Holdings Proposes to Amend Warrants Terms BEVERLY, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- , (; ) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has commercialized the for automated, genetic testing, announces that it intends to amend the exercise price of certain common share purchase warrants (the “Warrants”) originally issued on February 7 and February 18, 2022 to Meridian LGH Holdings, LLC and expiry five years after the date of issue. An aggregate of 18,500,000 Warrants were initially issued with an exercise price of CAD$0.45 per common s...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch